Research graph
References from An individual patient meta-analysis assessed the associations between change in albuminuria and acute changes in the glomerular filtration rate in randomized controlled trials of chronic kidney disease progression. Local targets link to admitted publications; unresolved targets remain external evidence.
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
10.1681/asn.2021070948 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials
10.1681/asn.2019010007 · 2019 · External reference
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
10.1038/s41591-023-02418-0 · 2023 · External reference
Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial
10.1093/ajh/5.7.423 · 1992 · External reference
Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial
10.1016/s0272-6386(96)90158-4 · 1996 · External reference
Efficacy and safety of benazepril for advanced chronic renal insufficiency
10.1056/nejmoa053107 · 2006 · External reference
Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure
10.1136/bmj.309.6958.833 · 1994 · External reference
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data
10.7326/0003-4819-135-2-200107170-00007 · 2001 · External reference
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group
10.1056/nejm199604113341502 · 1996 · External reference
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
10.1016/s0140-6736(98)10363-x · 1999 · External reference
Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
1997 · External reference
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
10.1001/jama.288.19.2421 · 2002 · External reference
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
10.1056/nejmoa011161 · 2001 · External reference
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
10.1007/s00125-011-2325-z · 2011 · External reference
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
10.1056/nejmoa011303 · 2001 · External reference
A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group
10.1056/nejm199205213262101 · 1992 · External reference
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group
10.1056/nejm199311113292004 · 1993 · External reference
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy
10.1681/asn.2011040378 · 2012 · External reference
Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study
10.1053/j.ajkd.2006.01.017 · 2006 · External reference
Angiotensin blockade in late autosomal dominant polycystic kidney disease
10.1056/nejmoa1402686 · 2014 · External reference
Blood pressure in early autosomal dominant polycystic kidney disease
10.1056/nejmoa1402685 · 2014 · External reference
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
10.1056/nejmoa1208799 · 2012 · External reference
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
10.1056/nejmoa0802987 · 2008 · External reference
Long-term comparison between captopril and nifedipine in the progression of renal insufficiency
10.1038/ki.1992.309 · 1992 · External reference
Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
2000 · External reference
The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group
10.1056/nejm199403313301301 · 1994 · External reference
Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial
10.1097/01.asn.0000103869.08096.4f · 2004 · External reference
Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy
10.1681/asn.2010010117 · 2010 · External reference
IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine
10.5301/jn.5000110 · 2013 · External reference
The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group
10.1681/asn.v1081772 · 1999 · External reference
A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy
10.1681/asn.v124791 · 2001 · External reference
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
10.1056/nejmoa1415463 · 2015 · External reference
Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study
10.1111/j.1523-1755.2004.00588.x · 2004 · External reference
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy
10.1093/ndt/gfp356 · 2009 · External reference
Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis
10.1681/asn.2004080686 · 2005 · External reference
A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy
10.1056/nejm198901053200102 · 1989 · External reference
Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group
10.1056/nejm199208273270904 · 1992 · External reference
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy
10.1681/asn.v93444 · 1998 · External reference
A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy
10.1053/j.ajkd.2005.10.016 · 2006 · External reference
Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial
10.1038/sj.ki.5002215 · 2007 · External reference
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
10.1056/nejmoa1504720 · 2015 · External reference
Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial
10.1053/j.ajkd.2014.11.016 · 2015 · External reference
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency
10.1681/asn.2006121372 · 2007 · External reference
Nurse practitioner care improves renal outcome in patients with CKD
10.1681/asn.2012121222 · 2014 · External reference
A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial
10.2215/cjn.07160810 · 2011 · External reference
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
10.1016/s0140-6736(11)60739-3 · 2011 · External reference
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
10.1016/s2213-8587(18)30314-0 · 2019 · External reference
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
10.1056/nejmoa1611925 · 2017 · External reference
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
2013 · External reference
A new equation to estimate glomerular filtration rate
10.7326/0003-4819-150-9-200905050-00006 · 2009 · External reference
Impact of Using the Race-Free 2021 CKD-EPI Creatinine Equation on Treatment Effects on GFR-Based Endpoints in Clinical Trials
2023 · External reference
Conducting Meta-Analyses in R with the metafor Package
10.18637/jss.v036.i03 · 2010 · External reference
Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD
10.1681/asn.0000000000000117 · 2023 · External reference
Handling missing within-study correlations in the evaluation of surrogate endpoints
10.1002/sim.9886 · 2023 · External reference
Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial
10.1001/jamanetworkopen.2025.1689 · 2025 · External reference
Glucocorticoids and control of glomerular filtration rate
1990 · External reference
Association Between Plasma Aldosterone Concentration and Intraglomerular Hemodynamics in Primary Aldosteronism
10.1093/ajh/hpae071 · 2024 · External reference
Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx
10.1016/j.kint.2018.08.024 · 2019 · External reference
